CN102307598A - TGF-β1抑制肽的药物制剂 - Google Patents

TGF-β1抑制肽的药物制剂 Download PDF

Info

Publication number
CN102307598A
CN102307598A CN2010800067872A CN201080006787A CN102307598A CN 102307598 A CN102307598 A CN 102307598A CN 2010800067872 A CN2010800067872 A CN 2010800067872A CN 201080006787 A CN201080006787 A CN 201080006787A CN 102307598 A CN102307598 A CN 102307598A
Authority
CN
China
Prior art keywords
tgf
peptide
cyclodextrin
emulsion
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800067872A
Other languages
English (en)
Chinese (zh)
Inventor
胡安·曼努埃尔·伊拉切·加雷塔
费尔南多·马丁内兹·加兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Digna Biotech SL
Original Assignee
Digna Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digna Biotech SL filed Critical Digna Biotech SL
Publication of CN102307598A publication Critical patent/CN102307598A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800067872A 2009-02-05 2010-02-04 TGF-β1抑制肽的药物制剂 Pending CN102307598A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900319 2009-02-05
ESP200900319 2009-02-05
PCT/ES2010/070062 WO2010089443A2 (es) 2009-02-05 2010-02-04 FORMULACIONES FARMACÉUTICAS DE PÉPTIDOS INHIBIDORES DE TGF- β1

Publications (1)

Publication Number Publication Date
CN102307598A true CN102307598A (zh) 2012-01-04

Family

ID=42320987

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800067872A Pending CN102307598A (zh) 2009-02-05 2010-02-04 TGF-β1抑制肽的药物制剂

Country Status (10)

Country Link
US (1) US20110294734A1 (cg-RX-API-DMAC7.html)
EP (1) EP2394666A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012516879A (cg-RX-API-DMAC7.html)
CN (1) CN102307598A (cg-RX-API-DMAC7.html)
AU (1) AU2010210033A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1008815A2 (cg-RX-API-DMAC7.html)
CA (1) CA2750559A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011008261A (cg-RX-API-DMAC7.html)
RU (1) RU2011136694A (cg-RX-API-DMAC7.html)
WO (1) WO2010089443A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9970057B2 (en) 2011-05-06 2018-05-15 Albert Einstein College Of Medicine, Inc. Human invasion signature for prognosis of metastatic risk
RU2678117C2 (ru) * 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
US9353149B2 (en) * 2013-05-10 2016-05-31 Southern Research Institute Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
KR101841748B1 (ko) * 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
AU2021409832A1 (en) * 2020-12-23 2023-08-10 Korea Institute Of Science And Technology NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-β SIGNALING AND USE THEREOF

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730969A (en) * 1988-10-05 1998-03-24 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
CN1839149A (zh) * 2003-08-22 2006-09-27 西玛生物医学信息公司 能够结合转化生长因子β1(TGF-β1)的肽
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
WO2008003685A1 (de) * 2006-07-06 2008-01-10 Henkel Ag & Co. Kgaa O/w-emulsion
WO2008013928A2 (en) * 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
CN101340927A (zh) * 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215520A (en) * 1991-09-17 1993-06-01 Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for delivering an active substance topically or percutaneously
US6132739A (en) * 1998-09-01 2000-10-17 Amway Corporation Makeup compositions and methods of making same
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
ES2371026T3 (es) * 2001-10-19 2011-12-26 Atritech, Inc. Dispositivo de oclusión ajustable en la orejuela auricular izquierda.
WO2003048323A2 (en) 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7279503B1 (en) * 2004-11-02 2007-10-09 Siltech Llc Water in oil emulsions
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730969A (en) * 1988-10-05 1998-03-24 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
CN1839149A (zh) * 2003-08-22 2006-09-27 西玛生物医学信息公司 能够结合转化生长因子β1(TGF-β1)的肽
CN101340927A (zh) * 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
WO2008003685A1 (de) * 2006-07-06 2008-01-10 Henkel Ag & Co. Kgaa O/w-emulsion
WO2008013928A2 (en) * 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
WO2021037290A3 (zh) * 2019-08-27 2021-04-15 南京安吉生物科技有限公司 一种融合多肽及其应用
GB2600594A (en) * 2019-08-27 2022-05-04 Nanjing Anji Biological Tech Co Ltd Fused polypeptide and use thereof

Also Published As

Publication number Publication date
CA2750559A1 (en) 2010-08-12
WO2010089443A3 (es) 2010-10-21
JP2012516879A (ja) 2012-07-26
EP2394666A2 (en) 2011-12-14
WO2010089443A2 (es) 2010-08-12
BRPI1008815A2 (pt) 2018-02-14
MX2011008261A (es) 2011-09-01
US20110294734A1 (en) 2011-12-01
RU2011136694A (ru) 2013-03-10
AU2010210033A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
JP2012516879A (ja) TGF−β1阻害剤ペプチドの医薬処方物
Deshayes et al. Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes
Liu et al. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis
Presas et al. Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin
EP4049653B1 (en) Injectable intraocular microgel as drug delivery system, and hydrogel comprising same
CN109789188A (zh) 具有低峰-谷比的pth化合物
JP2000505788A (ja) 巨大分子送達用の親油性ペプチド
CN113966226B (zh) 双重glp1/2激动剂的药物肠胃外组合物
Tavornvipas et al. Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor
JP7442595B2 (ja) ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤
CN103827187A (zh) 用β片层多肽嵌段共聚物功能化的生物活性碳纳米管复合材料及其制备方法
Kulkarni et al. Esterase-mediated sustained release of peptide-based therapeutics from a self-assembled injectable hydrogel
CN116997337A (zh) 半乳糖缺陷型免疫球蛋白的双官能降解剂
WO2018049329A1 (en) Formulations of cabozantinib
US20220040109A1 (en) Kidney-targeting drug delivery carrier
Silvestri et al. Physico-chemical studies of inclusion complex between hydrocortisone and cyclodextrins
Hao et al. Self-assembled doxorubicin prodrug riding on the albumin express train enable tumor targeting and bio-activation
Sampathi et al. Modified cyclodextrin-based thermosensitive in situ gel for voriconazole ocular delivery against fungal keratitis
Liu et al. Inclusion Complex of Nimodipine with Sulfobutylether-β-cyclodextrin: Preparation, Characterization, In Vitro and In Vivo Evaluation
JP5769420B2 (ja) Ncam由来の新規ペプチド(fgls)
Rodríguez-Cabello et al. Elastin-like proteins: molecular design for self-assembling
Mok et al. Dissolution of biomacromolecules in organic solvents by nano-complexing with poly (ethylene glycol)
ITMI20111866A1 (it) Polietilenglicoli modificati e loro complessi supramolecolari con macromolecole biologicamente attive
Lopez‐Silva et al. Antibody Labeling With FITC Facilitates Controlled Release From Peptide Hydrogels Bearing Fc‐Binding Motifs
CN114096848A (zh) 治疗性肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20120104

C20 Patent right or utility model deemed to be abandoned or is abandoned